These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 9001290)
1. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Stansell JD; Osmond DH; Charlebois E; LaVange L; Wallace JM; Alexander BV; Glassroth J; Kvale PA; Rosen MJ; Reichman LB; Turner JR; Hopewell PC Am J Respir Crit Care Med; 1997 Jan; 155(1):60-6. PubMed ID: 9001290 [TBL] [Abstract][Full Text] [Related]
2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862 [TBL] [Abstract][Full Text] [Related]
3. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876 [TBL] [Abstract][Full Text] [Related]
4. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183 [TBL] [Abstract][Full Text] [Related]
5. A decline in the pulmonary diffusing capacity does not indicate opportunistic lung disease in asymptomatic persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. Kvale PA; Rosen MJ; Hopewell PC; Markowitz N; Hansen N; Reichman LB; Wallace JM; Glassroth J; Fulkerson W; Meiselman L Am Rev Respir Dis; 1993 Aug; 148(2):390-5. PubMed ID: 8102043 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E; N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138 [TBL] [Abstract][Full Text] [Related]
7. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568 [TBL] [Abstract][Full Text] [Related]
8. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD; N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837 [TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of pneumocystis carinii pneumonia in AIDS patients]. Armbruster C; Hassl A; Kriwanek S Wien Klin Wochenschr; 1998 Sep; 110(17):604-7. PubMed ID: 9816629 [TBL] [Abstract][Full Text] [Related]
11. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172 [TBL] [Abstract][Full Text] [Related]
12. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526 [TBL] [Abstract][Full Text] [Related]
13. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Mansharamani NG; Balachandran D; Vernovsky I; Garland R; Koziel H Chest; 2000 Sep; 118(3):712-20. PubMed ID: 10988193 [TBL] [Abstract][Full Text] [Related]
14. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225 [TBL] [Abstract][Full Text] [Related]
16. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Morris AM; Huang L; Bacchetti P; Turner J; Hopewell PC; Wallace JM; Kvale PA; Rosen MJ; Glassroth J; Reichman LB; Stansell JD Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):612-6. PubMed ID: 10934095 [TBL] [Abstract][Full Text] [Related]
17. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l. Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL; AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983 [TBL] [Abstract][Full Text] [Related]
18. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064 [TBL] [Abstract][Full Text] [Related]
19. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Enomoto T; Azuma A; Kohno A; Kaneko K; Saito H; Kametaka M; Usuki J; Gemma A; Kudoh S; Nakamura S Respirology; 2010 Jan; 15(1):126-31. PubMed ID: 19947989 [TBL] [Abstract][Full Text] [Related]
20. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis. Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D; J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]